ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 3

Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

, , ,

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recent Guideline Updates in the Frontline Management of CLL
    EP. 2: Tailoring Treatment Approaches for Fit vs Unfit CLL Patients
    Now Viewing
    EP. 3: Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients
    EP. 4: Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data
    EP. 5: Clinical Insights and Real-World Evidence
    EP. 6: Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines
    EP. 7: Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options
    EP. 8: Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies
    EP. 9: Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy
    EP. 10: Relapse After Venetoclax-Based Therapy: Early vs Late Management
    EP. 11: Progression on BTK Inhibitors: Treatment Options and Considerations
    EP. 12: Emerging Agents and Future Strategies in Relapsed/Refractory CLL
    EP. 13: Reflections and Future Directions in CLL Management

    Video content above is prompted by the following:

    • Briefly review recent ESMO guideline updates for the frontline management of patients with IGHV-unmutated or mutated and no TP53 mutation and discuss associated implications.
    x